Equities researchers at Guggenheim began coverage on shares of Tyra Biosciences (NASDAQ:TYRA - Get Free Report) in a report released on Friday, Benzinga reports. The brokerage set a "buy" rating and a $55.00 price target on the stock. Guggenheim's price target suggests a potential upside of 178.76% from the stock's previous close.
Other research analysts have also recently issued research reports about the company. William Blair upgraded Tyra Biosciences to a "strong-buy" rating in a report on Wednesday, September 23rd. Raymond James Financial reaffirmed a "strong-buy" rating and set a $50.00 target price on shares of Tyra Biosciences in a research report on Tuesday, October 6th. Wedbush boosted their price target on Tyra Biosciences from $53.00 to $57.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tyra Biosciences in a research note on Thursday, October 15th. Finally, HC Wainwright decreased their price target on shares of Tyra Biosciences from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $47.50.
View Our Latest Stock Report on TYRA
Tyra Biosciences Stock Up 0.6%
NASDAQ TYRA opened at $19.73 on Friday. Tyra Biosciences has a 1-year low of $16.86 and a 1-year high of $40.65. The business has a 50 day moving average price of $21.30 and a 200 day moving average price of $29.15.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.07). On average, analysts predict that Tyra Biosciences will post -2.78 EPS for the current year.
Hedge Funds Weigh In On Tyra Biosciences
Large investors have recently added to or reduced their stakes in the company. Soleus Capital Management L.P. acquired a new position in Tyra Biosciences in the third quarter worth $9,733,000. Integral Health Asset Management LLC acquired a new stake in shares of Tyra Biosciences during the third quarter worth $9,951,000. Entropy Technologies LP bought a new stake in shares of Tyra Biosciences during the 3rd quarter valued at about $321,000. Steward Partners Investment Advisory LLC lifted its holdings in Tyra Biosciences by 2,787.5% in the third quarter. Steward Partners Investment Advisory LLC now owns 35,430 shares of the company's stock worth $775,000 after acquiring an additional 34,203 shares during the last quarter. Finally, HighVista Strategies LLC lifted its stake in Tyra Biosciences by 23.1% in the third quarter. HighVista Strategies LLC now owns 227,436 shares of the company's stock valued at $4,974,000 after buying an additional 42,662 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company's pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.